Prothena Corp. (PRTA) Reports Statistically Significant Data from PRX002 Phase 1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures falter as Meta Platforms weighs on megacaps
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Wedbush Reiterates Bullish Rating, $46 PT on Prothena (PRTA) Following PRX002 Data
March 20, 2015 8:32 AM EDTWedbush analyst Heather Behanna reiterated an Outperform rating and $46 price target on Prothena Corp (NASDAQ: PRTA) after the company and partner Roche announced data from a first-in-human study of PRX002, an anti-alpha-synuclein monocloncal antibody in development for Parkinson's disease (PD); the first time an anti-alpha-synuclein antibody has been tested in humans.
Behanna commented, "The study in... More
Prothena Corp (PRTA) Price Target Raised to $50 at RBC Capital
March 20, 2015 7:17 AM EDTRBC Capital maintained an Outperform rating on Prothena Corp (NASDAQ: PRTA) and raised its price target to $50.00 (from $40.00). Yesterday the company reported solid data in Parkinson's. Analyst Michael J. Yee said Prothena was shifting to a "two drug" company.
"We continue to think Prothena represents a very interesting and compelling small... More
